Scinai Immunotherapeutics (SCNI) Gross Profit (2024 - 2026)

Scinai Immunotherapeutics has reported Gross Profit for 3 years, with the latest figure at -$1.1 million in Q1 2026.

• Quarterly Gross Profit fell 590.35% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.6 million (changed N/A YoY) and the FY2025 annual result came in at -$4.3 million, down 647.24% from the prior year.
• Gross Profit improved to -$1.1 million in Q1 2026 per SCNI's latest filing, from -$1.5 million in the prior quarter.
• Over five years, Gross Profit peaked at $228000.0 in Q1 2025 and troughed at -$1.5 million in Q2 2025.
• A 3-year average of -$560800.0 and a median of -$249000.0 in 2024 frame the typical range for Gross Profit.
• The widest YoY moves for Gross Profit: up 590.35% in 2026, down 590.35% in 2026.
• Over 3 years, Gross Profit stood at -$167000.0 in 2024, then plunged by 797.01% to -$1.5 million in 2025, then increased by 25.37% to -$1.1 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered -$1.1 million, -$1.5 million, and $228000.0 for Q1 2026, Q2 2025, and Q1 2025 respectively.